论文部分内容阅读
1988年美国国立卫生研究院(NIH)的一个联合委员会(JNC)修订了高血压“阶梯治疗”方案。在推荐的第一线治疗药中加了钙拮抗剂和血管紧张素转换酶抑制剂(ACEI),药物的选择和调整由医生根据病人的情况而定。 对五大洲九个国家的部分临床医师和世界知名的高血压专家就“高血压阶梯治疗”方案作了非正式调查的结果,发现多数人不赞成此方案而主张因人施治。并认为在用药前应先进行非药物治疗包括
A joint committee of the National Institutes of Health (NIH) in 1988 revised the “ladder treatment” of hypertension program. Calcium antagonists and angiotensin-converting enzyme inhibitors (ACEIs) have been added to the recommended first-line therapies, and the choice and adjustment of medications is based on the patient’s condition. As a result of an informal survey of “Hypertensive Step Therapy” programs by some clinicians in nine countries on five continents and world-renowned hypertensive experts, most people disagreed with the proposal and advocated treatment based on human factors. And that before the drug should be non-drug treatment include